Reevaluation of CYP2D6 Genotyping May Open Tamoxifen Treatment to More Breast Cancer Patients

Reevaluation of CYP2D6 Genotyping May Open Tamoxifen Treatment to More Breast Cancer Patients
shutterstock_129857873Despite clinical recommendations against using Cytochrome P450 2D6 (CYP2D6) gene expression as a guide for tamoxifen therapy for breast cancer patients, a study from the Mayo Clinic suggests otherwise. The laboratory of Matthew Goetz, MD, writing in the journal article "Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies," published in Journal of the National Cancer Institute, suggests that the trials on which the recommendations were based were prone to error. "The potential benefit of CYP2D6 testing is obvious but has been difficult to establish," said Dr. Goetz in a news release from Mayo Clinic. "One major reason appears to be the lack of analytical validity. We found that if you use tumor tissue to determine the CYP2D6 genotype a patient was born with, you are going to get it wrong a substantial portion of the time." Dr. Goetz and colleagues showed that up to 45% of breast cancer tumors lose one of the two parental CYP2D6 alleles the
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.